<?xml version="1.0" encoding="UTF-8"?>
<p>Osteoarthritis (OA) is one of the most common debilitating diseases encountered globally. The clinical symptoms of OA are pain and stiffness in joints. It affects women more than men [
 <xref rid="B1-molecules-26-01831" ref-type="bibr">1</xref>]. 80% of patients with OA have some degree of movement impairment. This leads to diminished performance in the workplace, and 25% of patients cannot perform the main activities of their daily life, which often leads to social isolation and depression [
 <xref rid="B2-molecules-26-01831" ref-type="bibr">2</xref>]. Despite decades of drug research and development, no disease-modifying drug for osteoarthritis has been approved for use in humans [
 <xref rid="B3-molecules-26-01831" ref-type="bibr">3</xref>]. Such a drug could slow progression by reducing the rate of cartilage degeneration. Nowadays, available pharmacotherapies focus on pain relief only after symptoms are present, by the use of acetaminophen, cyclooxygenase-2 (COX2) inhibitors and corticosteroids.
</p>
